Michael Liontos
Overview
Explore the profile of Michael Liontos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lyrarakis G, Liontos M, Anastasopoulou A, Bouros S, Gkoufa A, Diamantopoulos P, et al.
Front Oncol
. 2024 Oct;
14:1420879.
PMID: 39435288
Background: Programmed cell death 1 receptor (PD-1) inhibition as monotherapy followed by Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibition in case of progression or as upfront double co-inhibition has drastically...
2.
Axiaris G, Ioannou A, Papoutsaki M, Marinos L, Liontos M, Michopoulos S, et al.
F1000Res
. 2023 Oct;
11:424.
PMID: 37867623
The cornerstone of inflammatory bowel disease (IBD) treatment is immunomodulators. IBD patients are at increased risk of intestinal and extraintestinal malignancy. Ustekinumab is a fully humanized monoclonal anti-IL12/23 antibody with...
3.
Paschou S, Liontos M, Eleftherakis-Papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, et al.
Front Oncol
. 2022 Apr;
12:847917.
PMID: 35402216
Aim: The aim of this study was to investigate the association of endocrine complications after ICI immunotherapy with progression-free survival (PFS) and overall survival (OS) in a large single-center oncological...
4.
Kyriazoglou A, Kaparelou M, Goumas G, Liontos M, Zakopoulou R, Zografos E, et al.
Breast Care (Basel)
. 2022 Mar;
17(1):63-70.
PMID: 35355696
Introduction: The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors...
5.
Aravantinou-Fatorou A, Andrikopoulou A, Liontos M, Fiste O, Georgakopoulou V, Dimopoulos M, et al.
Oncol Lett
. 2021 Oct;
22(6):821.
PMID: 34691248
Recently, immunotherapy has shown promising results in solid tumors. To the best of our knowledge, this is the first systematic review of published literature synthesizing all the available data and...
6.
Fiste O, Liontos M, Koutsoukos K, Terpos E, Dimopoulos M, Zagouri F
Ann Transl Med
. 2021 Jan;
8(23):1603.
PMID: 33437802
Breast carcinoma is the most frequent and the second leading cause of cancer mortality in women worldwide. Current treatment decisions are based on tumor profiling of the initial tissue biopsy....
7.
Zagouri F, Dedes N, Papatheodoridi A, Liontos M, Dimopoulos M
BMC Pregnancy Childbirth
. 2020 Dec;
20(1):747.
PMID: 33261562
While pregnancy-related malignancies are quite rare, their incidence is increasing and thus affecting more and more women nowadays. Their management, however, with both chemotherapy and supportive agents remains quite challenging...
8.
Papaxoinis G, Athanasiadis A, Sgouros J, Visvikis A, Drizou M, Kontopodis E, et al.
J Oncol
. 2020 Oct;
2020:5304516.
PMID: 33014051
Background: During the last decade, significant improvement was made in systemic therapy of pancreatic adenocarcinoma (PAC). The impact of this progress in everyday clinical practice has not been fully described...
9.
Fizazi K, Kramer G, Eymard J, Sternberg C, de Bono J, Castellano D, et al.
Lancet Oncol
. 2020 Sep;
21(11):1513-1525.
PMID: 32926841
Background: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and...
10.
Skafida E, Triantafyllopoulou I, Flessas I, Liontos M, Koutsoukos K, Zagouri F, et al.
Case Rep Oncol
. 2020 Aug;
13(2):627-632.
PMID: 32774247
Cutaneous metastases from visceral carcinomas are relatively uncommon, with an overall incidence ranging from 0.7 to 9%. Diagnosis of scalp metastases usually escapes clinicians and dermatologists due to the fact...